Do you want to read an article? Please log in or register.
Mortality after treatment of malignant pleural effusions with indwelling pleural catheters versus chemical pleurodesis: a population-based study
Pleural DiseasesFurther Publications
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C, GFPC 08–2015 ENERGY investigators
doi: 10.1016/S2213-2600(24)00264-9
COMMENTED
Pleural DiseasesPneumonia
The Impact of clinically significant pleural effusion on survival of US Veterans with cancer, congestive heart failure, and pneumonia: The Veterans Administration Lung Effusion Study (VALUES)
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
Chest
Chopra A, Hu K, Gemoets DE, Judson MA
doi: 10.1016/j.chest.2025.02.003
Asthma
Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study
Eur Respir J
Sheng-Kai Ma K, Brumbaugh B, Saff RR, Phipatanakul W, Yun-Chen Tsai S, Westmeijer M, Holt A, Ebriani J, Camargo CA Jr, Chen ST
doi: 10.1183/13993003.00139-2025
RECOMMENDED
Asthma
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE
doi: 10.1183/13993003.00316-2024
Lung Cancer
Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain
Lung Cancer
Teixidor-Vilà E, Trallero J, Puigdemont M, Vidal-Vila A, Hernandez-Martínez A, Sais E, Sabaté-Ortega J, Verdura S, Menendez JA, Bosch-Barrera J, Sanvisens A, Marcos-Gragera R
doi: 10.1016/j.lungcan.2024.107995
RECOMMENDED
COPD
Does Chronic Obstructive Pulmonary Disease Impact Outcome after Coronary Artery Bypass Grafting? A Population-Based Retrospective Study in Germany
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med
Hochhausen N, Sales MC, Ramnath NWM, Billig S, Kork F, Moza A
doi: 10.3390/jcm13175131
RECOMMENDED
Lung Cancer
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A
doi: 10.1016/j.lungcan.2025.108548
Pleural Diseases
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)
Eur Respir J
Kanellakis NI, Antoun E, Cano-Gamez K, Chu J, Manoharan N, Berridge G, Vendrell I, Zhang Z, Corcoran JP, Elsheikh A, Dong T, Fischer R, Whalley JP, Knight JC, Rahman NM
doi: 10.1183/13993003.00010-2025
Pulmonary Fibrosis
Antifibrotic drug treatment of patients with idiopathic pulmonary fibrosis in Sweden: A registry-based observational study
Chron Respir Dis
Carlson L, Kalafatis D, Pesonen I, Magnusson JM, Skold M
doi: 10.1177/14799731241299443